Health Catalyst, Inc. (NASDAQ:HCAT) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. cut its position in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 13.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 497,295 shares of the company's stock after selling 75,766 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.82% of Health Catalyst worth $3,516,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Quest Partners LLC acquired a new position in Health Catalyst during the 3rd quarter valued at about $34,000. Quadrature Capital Ltd acquired a new position in shares of Health Catalyst during the third quarter valued at about $84,000. Stoneridge Investment Partners LLC purchased a new position in shares of Health Catalyst in the 4th quarter valued at approximately $77,000. Intech Investment Management LLC acquired a new stake in Health Catalyst in the 3rd quarter worth approximately $145,000. Finally, Dynamic Advisor Solutions LLC purchased a new stake in Health Catalyst during the 4th quarter worth approximately $180,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, General Counsel Benjamin Landry sold 13,827 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the sale, the general counsel now owns 160,437 shares of the company's stock, valued at approximately $729,988.35. This represents a 7.93 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.51, for a total transaction of $39,119.59. Following the completion of the transaction, the chief operating officer now directly owns 91,253 shares in the company, valued at $685,310.03. This trade represents a 5.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,530 shares of company stock worth $299,572. 2.50% of the stock is owned by corporate insiders.

Remove Ads

Wall Street Analysts Forecast Growth

HCAT has been the subject of several research reports. Stifel Nicolaus lowered their price objective on shares of Health Catalyst from $10.00 to $5.00 and set a "hold" rating for the company in a research note on Thursday, February 27th. Canaccord Genuity Group lowered their price target on Health Catalyst from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, January 21st. Royal Bank of Canada cut their price objective on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a report on Thursday, February 27th. Citigroup reduced their price objective on Health Catalyst from $10.50 to $10.00 and set a "buy" rating for the company in a research note on Friday, January 10th. Finally, Piper Sandler dropped their target price on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 11th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, Health Catalyst presently has an average rating of "Moderate Buy" and an average price target of $9.27.

Health Catalyst Price Performance

Health Catalyst stock traded down $0.02 during midday trading on Monday, reaching $4.53. The company had a trading volume of 686,071 shares, compared to its average volume of 614,703. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst, Inc. has a 12-month low of $3.76 and a 12-month high of $9.24. The company has a market capitalization of $318.06 million, a P/E ratio of -3.36 and a beta of 1.41. The firm's fifty day simple moving average is $5.01 and its 200-day simple moving average is $6.83.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.